Signature Wealth Management Group Purchases 20,873 Shares of Pfizer Inc. (NYSE:PFE)

Signature Wealth Management Group grew its position in Pfizer Inc. (NYSE:PFE) by 15.7% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 153,511 shares of the biopharmaceutical company’s stock after buying an additional 20,873 shares during the period. Pfizer accounts for about 1.5% of Signature Wealth Management Group’s portfolio, making the stock its 27th largest position. Signature Wealth Management Group’s holdings in Pfizer were worth $3,890,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Community Trust & Investment Co. boosted its stake in Pfizer by 4.8% in the first quarter. Community Trust & Investment Co. now owns 118,372 shares of the biopharmaceutical company’s stock valued at $3,000,000 after acquiring an additional 5,389 shares in the last quarter. Stockman Wealth Management Inc. lifted its holdings in shares of Pfizer by 23.0% during the 1st quarter. Stockman Wealth Management Inc. now owns 355,871 shares of the biopharmaceutical company’s stock valued at $9,018,000 after purchasing an additional 66,496 shares during the last quarter. Claris Advisors LLC MO boosted its position in shares of Pfizer by 132.9% in the 1st quarter. Claris Advisors LLC MO now owns 25,668 shares of the biopharmaceutical company’s stock worth $650,000 after purchasing an additional 14,647 shares in the last quarter. Boothe Investment Group Inc. grew its stake in Pfizer by 2.9% during the 1st quarter. Boothe Investment Group Inc. now owns 277,296 shares of the biopharmaceutical company’s stock worth $7,027,000 after buying an additional 7,804 shares during the last quarter. Finally, FNY Investment Advisers LLC grew its stake in Pfizer by 25.6% during the 1st quarter. FNY Investment Advisers LLC now owns 16,910 shares of the biopharmaceutical company’s stock worth $428,000 after buying an additional 3,446 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of several recent analyst reports. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group lifted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Trading Down 1.3%

NYSE PFE opened at $24.51 on Monday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $139.35 billion, a PE ratio of 17.38, a P/E/G ratio of 0.64 and a beta of 0.57. The company has a fifty day moving average of $23.06 and a 200 day moving average of $24.95.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.82 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.02%. The ex-dividend date was Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.